

Application No.: 10/518,067

MG-2519

**IN THE CLAIMS:**

1. (cancel)

2. (currently amended) The method as claimed in claim [[13]] 7, characterized in that the adjuvant is an adjuvant for hemogenous medicaments or active ingredients.

3. (previously presented) The method as claimed in claim 2, characterized in that the adjuvant is gaseous.

4. (previously presented) The method as claimed in 3, characterized in that the adjuvant is administered by inhalation.

5. (cancel)

6. (cancel)

7. (currently amended) ~~The hemogenous medicament as claimed in claim 6, characterized in that the additional~~ In a method of treating a patient characterized in that a xenon adjuvant is provided in a form selected from the group consisting of xenon and a xenon containing gas mixture, administering the adjuvant and at least one medicament to a patient to assist the medicament wherein the xenon is in a subanesthetic amount whereby what is administered to the patient contains no more than 70% by volume of xenon and when the adjuvant itself contains more than 70% by volume xenon the adjuvant is metered into the patient's respiratory gas so that the combined gas supplied to the patient contains from 5 to 70% by volume xenon, and the medicament is active for treating a condition to be treated by a comprises at least one medicament selected from the group consisting of medicaments with an antiviral, antibacterial,

Application No.: 10/518,067

MG-2519

antimycotic, neuroprotective, anticarcinogenic, sedative, analgesically or anesthetically acting substance; opioids; sufentanil, remifentanil; anesthetics, volatile anesthetics; methoxyflurane, halothane, enflurane, isoflurane, sevoflurane and desflurane; local anesthetics; articaine, benzovaine, bupivacaine, butanilicaine, butoxycaine, cinchocaine, cocaine, etidocaine, fomocaine, lidocaine, mepivacaine, oxetacaine, oxybuprocaine, pramocaine, prilocaine, procaine, proxymetacaine, ropivacaine, tolycaine or tetracaine; 2-adrenoceptor agonists, clonidine, dexmedetomidine; catecholamines, parasympathomimetics, parasympatholytics, spasmolytics, sympathomimetics, sympatholytics,  $\beta$ -receptor blocks, tranquilizers, narcoleptics, antidepressants, sedatives, centrally sedative sedating agents, analgesics, antipyretics, migraine remedies, antiparkinson agents, analeptics, antiepileptics, antiemetics, emetics, substances influencing blood clotting, amino acids, vitamins or hormones; medicaments for NOS inhibition, medicaments for treating migraine, medicaments for treating septic shock, medicaments for treating multiple sclerosis, medicaments for treating inflammations or inflammatory pains; hemogenous cerebral medicaments; medicaments for the treatment and/or prophylaxis of stroke, reperfusion damage, brain trauma, of impairments of blood flow in the brain, of impairment of cerebral perfusion, of cognitive impairments or of postischemia syndrome; barbiturates; barbital or phenobarbital, allobarbital, amobarbital, aprobarbital, brallobarbital, cyclobarbital, pentobarbital, proallylanol, secobarbital and vinylbital, chloral hydrate, methylpentynol, paraldehyde; benzodiazepines, alprazolam, bromazepam, brotizolam, diazepam, flunitrazepam, flurazepam, loprazolam, lormetazepam, midazolam, nitrazepam, oxazepam, temazepam and triazolam; medicaments for neuroprotection, medicaments for the prophylaxis and/or therapy of impairments of cognitive performance; medicaments for Parkinson's disease, Alzheimer's

Application No.; 10/518,067

MG-2519

disease; organic brain syndrome, depressive pseudodementias, dementing syndromes, deliria as acute organic brain syndromes, intoxications, withdrawal syndromes or cytopathic influences; medicaments for chronic neurodegenerative disorders; medicaments for Huntington's disease, amyotropically lateral sclerosis, Parkinson's disease, AIDS dementia, Alzheimer's disease or acute neurodegenerative disorders; medicaments for ischemias of the brain or neurotraumata; diagnostic aids, x-ray contrast agents or radioactive isotopes, selecting as a patient some one having such condition, and administering both the xenon adjuvant and the medicament to the patient having such condition.

8. (cancel)

9. (currently amended) The method as claimed in claim [[14]] 7, characterized in that the adjuvant is administered with at least one medicament for the treatment of acute and chronic cerebral disorders or impairments or a medicament for the treatment and/or prophylaxis of ischemic brain disorders or the sequelae of a cerebral ischemia or the adjuvant is administered with at least one medicament for the treatment and/or prophylaxis of stroke, reperfusion damage or brain trauma.

10. (currently amended) The method as claimed in claim [[13]] 9, characterized in that the adjuvant is gaseous.

11. (currently amended) The method as claimed in claim [[13]] 9, characterized in that the adjuvant is administered by inhalation.

12. (cancel)

13. (cancel)

14. (cancel)